A multi-site longitudinal cohort study of Prodromal and Clinical Parkinson’s Disease

Parkinson’s disease (PD) develops slowly and is characterized by progressive and fluctuating motor changes. People with REM-sleep behavior disorder (RBD) are at risk of developing Parkinson’s disease in the future, and so may have mild motor changes. In general, it is difficult to monitor motor changes in Parkinson’s disease and REM sleep behavior disorder, because they can change from day to day.

Smartphones offer a potential solution to these challenges because they enable your motor state to be remotely and frequently monitored. The Roche PD Mobile Application v2 smartphone app combines active testing (small tests you do every day) with passive monitoring (the phone reading your mobility while you go about your day) to detect more subtle signs and symptoms of change.

The primary objective of this study is to determine whether data acquired from such a remote monitoring approach can reliably and validly identify and track motor and non-motor symptoms in REM sleep behavior disorder and clinical PD.

For this study, 230 male and female participants will be recruited across 4 groups, at approximately 6 sites in Canada.

The Parkinson’s Progression Markers Initiative (PPMI) 2.0 Clinical – Establishing a Deeply Phenotyped PD Cohort

The purpose of this study is to obtain information from people with and without Parkinson disease (PD) so that researchers may better understand how Parkinson disease progresses, in order to inform better treatments.

More information

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early Parkinson’s Disease

Currently, there is no approved medication to modify the progression of Parkinson’s disease (PD).

The PADOVA (Roche BN42358) clinical trial is studying the safety and efficacy of a drug for individuals with early Parkinson’s disease.

• Aged 50 to 85, diagnosed with PD for at least 6 months and up to 3 years
• Currently taking no more than 1 medication for PD (maximum daily dose of 450 mg of levodopa, 1 mg of rasagiline, or 10 mg of selegiline)
• Able to undergo medical procedures such as MRI and DaTScans
• Willing to use a smartphone application and smartwatch for the duration of the study
• The study will last at least  76 weeks
• There is no compensation for this study. However, costs related to participation in the study, such as travel and meals during visit days, will be reimbursed.